TET2 and myeloproliferative disorder: One study that investigated mutations in 63 patients with AML secondary to an MPN found that mutations in TET2 were acquired at transformation in 43% of cases [190], and the acquisition of mutations in TET2 in patients with PV JAK2V617F was associated with transformation to AML and reduced survival [120].